COVID-19 Vaccines
Types of COVID-19 vaccines in the US, including those approved by the FDA under Emergency Use Authorization, as well as other investigational products currently in Phase 3 clinical trials.
Infectious Disease
FDA: Sotrovimab No Longer Authorized to Treat COVID-19 in Any US Region
As of April 5, 2022, CDC Nowcast data reported that the BA.2 subvariant accounted for more than 50% of cases in all US states and territories.
Racial/Ethnic Minorities Report COVID-19-Related Discrimination
Prevalence of discrimination was reported to be higher among all racial/ethnic minorities than among White participants; those who identify as Asian or American Indian/Alaska Native were most likely to have experienced hostile behavior.
Oral Treatment for COVID-19 Gains Fast Track Designation
EDP-235 is currently being examined in a first-in-human phase 1 trial to assess safety, tolerability, and pharmacokinetics.
Safety, Tolerability, Immunogenicity of the Novel Pneumococcal Conjugate Vaccine V114 in Patients at Risk for Pneumococcal Disease
Researchers sought to assess the safety, tolerability, and immunogenicity of a novel pneumococcal conjugate vaccine (V114) in patients at risk for pneumococcal disease.
Sequential Mechanical Ventilation Effective in Treating Tuberculosis With Respiratory Failure
The researchers assessed the efficacy and safety of sequential mechanical ventilation in the treatment of tuberculosis with respiratory failure.
Oral-Only Dosing Regimen of Omadacycline Approved for CABP
Previously, the initial loading dose of Nuzyra for CABP was administered only by IV infusion.
FDA: Current Data Do Not Support Leronlimab for COVID-19
Results showed both trials of leronlimab did not meet primary or secondary endpoints.
Invasive Aspergillosis Superinfection Possible in Symptomatic COVID-19
Critically ill patients hospitalized with COVID-19 — particularly those who develop ARDS — may also experience an opportunistic aspergillosis superinfection.
- Loading...
Loading...
Next post in Lung Infection
Loading... 
Loading...